We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regentis Biomaterials (NYSE American: RGNT) Builds Commercial and Regulatory Momentum as GelrinC Advances Toward Key Milestones
Regentis is advancing GelrinC through a pivotal stage of development, with key catalysts including U.S. clinical study enrollment, European commercialization activities, and continued manufacturing optimization.
Strategic interest in cartilage regeneration technologies was highlighted by Smith+Nephew’s acquisition of CartiHeal for up to $330 million, underscoring the potential value of innovative orthopedic solutions designed to address unmet needs in cartilage repair.
GelrinC is an off-the-shelf, cell-free, one-step hydrogel-based implant designed to simplify cartilage repair through a procedure that supports and mimics the body’s natural regenerative processes.
Cartilage Regeneration Gains Strategic Validation
The orthopedic industry is increasingly focused on technologies that can address cartilage damage by promoting tissue regeneration rather than simply managing symptoms. This opportunity gained additional validation when Smith+Nephew completed its acquisition of CartiHeal, a developer of cartilage repair technology, in a transaction valued at up to $330 million. The acquisition demonstrated growing strategic interest among major orthopedic companies in regenerative approaches designed to improve joint repair outcomes and expand treatment options for patients suffering from cartilage defects.
Within this evolving market landscape, Regentis Biomaterials (NYSE American: RGNT) is advancing GelrinC, its proprietary hydrogel-based cartilage regeneration platform designed to provide an off-the-shelf, cell-free solution for cartilage repair. Unlike traditional approaches that may require cell harvesting, laboratory expansion, or more complex treatment workflows, GelrinC is…
This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NYSE American: RGNT) as part of a paid investor awareness and marketing engagement.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT
View the Zacks #1 Rank List
Regentis Biomaterials (NYSE American: RGNT) Builds Commercial and Regulatory Momentum as GelrinC Advances Toward Key Milestones
Cartilage Regeneration Gains Strategic Validation
The orthopedic industry is increasingly focused on technologies that can address cartilage damage by promoting tissue regeneration rather than simply managing symptoms. This opportunity gained additional validation when Smith+Nephew completed its acquisition of CartiHeal, a developer of cartilage repair technology, in a transaction valued at up to $330 million. The acquisition demonstrated growing strategic interest among major orthopedic companies in regenerative approaches designed to improve joint repair outcomes and expand treatment options for patients suffering from cartilage defects.
Regentis Advances GelrinC Toward Multiple Milestones
Within this evolving market landscape, Regentis Biomaterials (NYSE American: RGNT) is advancing GelrinC, its proprietary hydrogel-based cartilage regeneration platform designed to provide an off-the-shelf, cell-free solution for cartilage repair. Unlike traditional approaches that may require cell harvesting, laboratory expansion, or more complex treatment workflows, GelrinC is…
Read More>>
This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NYSE American: RGNT) as part of a paid investor awareness and marketing engagement.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
Read full article here »